EU Parliament supports reinforced role for European Medicines Agency in benefit to consumers

Your substances


The European Parliament has voted to give greater powers to the European Medicines Agency (EMA) to help it better manage public health crises and improve access to critical medicines and medical devices for consumers. One of the early consequences of the COVID pandemic was a shortage of muscle relaxants, sedatives and pain-killing drugs, particularly in hospital intensive care units, as health systems struggled to deal with the wave of hospital patients suffering from COVID-19. The shortage of raw materials for these medicines also drove up costs of common painkillers bought over-the-counter.



Related News